Literature DB >> 29452091

Expression profiles and clinical value of plasma exosomal Tim-3 and Galectin-9 in non-small cell lung cancer.

Jianwei Gao1, Xiangyu Qiu2, Xinying Li1, Hang Fan1, Fang Zhang1, Tangfeng Lv3, Yong Song4.   

Abstract

Exosomes are membrane-bound, virus-sized vesicles present in circulating blood. Tumor cells are avid producers of exosomes, which are thought to mimic molecular features of parent tumor cells. T-cell immunoglobulin- and mucin-domain-containing molecule 3 (Tim-3) is a the next-generation immune checkpoint that can be activated by its ligand Galectin-9 to negatively regulate the anti-tumor immune response. However, the characteristics of plasma exosomal Tim-3 and Galectin-9 (Exo-T/G) in cancer remained unknown. This study was conducted to investigate the expression patterns and clinical value of plasma exosomal total protein (Exo-pro) and Exo-T/G in non-small cell lung cancer (NSCLC). Plasma was collected from 103 NSCLC patients including 60 early stages and 43 advanced stages disease samples as well as 56 healthy subjects. Exosomes were isolated from plasma by commercial exosome precipitation solution and identified by western blotting of CD63 and transmission electron microscopy. Exo-pro concentration was measured by the BCA assay. Enzyme-linked immunosorbent assay was used to quantify Exo-T/G. Additionally, 34 NSCLC samples were applied to directly detect plasma TIM-3 (Plas-T) and Galectin-9 (Plas-G). Our results showed that Exo-pro, Exo-T, and Exo-G were significantly increased in NSCLC plasma compared to that in the healthy samples. High levels of Exo-T and Exo-G were all positively correlated with several malignant parameters, including larger tumor size, advanced stages, and more distant metastasis. High levels of Exo-pro and Exo-T were also correlated with more lymph node metastasis. Additionally, plasma from lung squamous cell carcinoma showed higher Exo-T and Exo-G compared with that from lung adenocarcinoma. ALK-positive patients showed to have decreased Exo-T and Exo-G levels. Pearson's correlation analysis revealed a significant correlation between Exo-pro and Exo-T/G, Exo-T and Exo-G, Exo-T and Plas-T, Exo-G and Plas-G, and Plas-T and Plas-G. Together, our data revealed that Exo-pro, especially Exo-T and Exo-G could be potential biomarkers for NSCLC. Further studies focusing on pure tumor-derived exosomes isolated from plasma were needed.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Exosomes; Galectin-9; Immune checkpoints; Non-small cell lung cancer; Tim-3

Mesh:

Substances:

Year:  2018        PMID: 29452091     DOI: 10.1016/j.bbrc.2018.02.114

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  28 in total

Review 1.  The biological functions and clinical applications of exosomes in lung cancer.

Authors:  Rui Chen; Xin Xu; Zijun Qian; Congcong Zhang; Yongjie Niu; Zhixian Wang; Jianli Sun; Xiao Zhang; Yongchun Yu
Journal:  Cell Mol Life Sci       Date:  2019-07-27       Impact factor: 9.261

2.  Lipid Metabolism and Immune Checkpoints.

Authors:  Qianjin Liao; Yujuan Zhou; Longzheng Xia; Deliang Cao
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

3.  Characterization of Protein Profiling and mRNA Expression of LLC Exosomes.

Authors:  Wen Zhang; Pei He; Shibei Wang; Amila Adili; Zixuan Chen; Chen-Yu Zhang; Xiaohong Jiang; Jing Li; Yujing Zhang
Journal:  Protein J       Date:  2019-10       Impact factor: 2.371

Review 4.  Emerging roles of exosome-derived biomarkers in cancer theranostics: messages from novel protein targets.

Authors:  Jiongjia Cheng; Xiaofeng Wang; Xuechun Yuan; Guangxiang Liu; Qian Chu
Journal:  Am J Cancer Res       Date:  2022-05-15       Impact factor: 5.942

Review 5.  Exosomes carrying immune checkpoints, a promising therapeutic approach in cancer treatment.

Authors:  Hadi Sahrai; Erfan Rezazadeh-Gavgani; Yalda Yazdani; Amirreza Khalaji; Seyed Ziaeddin Rasihashemi; Parisa Lotfinejad
Journal:  Med Oncol       Date:  2022-09-07       Impact factor: 3.738

Review 6.  Exosomes: a new perspective in EGFR-mutated lung cancer.

Authors:  Amina Jouida; Cormac McCarthy; Aurelie Fabre; Michael P Keane
Journal:  Cancer Metastasis Rev       Date:  2021-04-14       Impact factor: 9.264

7.  The TIM3/Gal9 signaling pathway: An emerging target for cancer immunotherapy.

Authors:  Sashi Kandel; Pratik Adhikary; Guangfu Li; Kun Cheng
Journal:  Cancer Lett       Date:  2021-04-22       Impact factor: 9.756

Review 8.  [Advances in Exosomes in the Pathogenesis and Diagnosis of Lung Cancer].

Authors:  Huanhuan Bi; Dunqiang Ren; Jun Zhang; Hongmei Wang
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2020-07-20

Review 9.  microRNAs Shape Myeloid Cell-Mediated Resistance to Cancer Immunotherapy.

Authors:  Elena Daveri; Elisabetta Vergani; Eriomina Shahaj; Laura Bergamaschi; Stefano La Magra; Michela Dosi; Chiara Castelli; Monica Rodolfo; Licia Rivoltini; Viviana Vallacchi; Veronica Huber
Journal:  Front Immunol       Date:  2020-07-22       Impact factor: 7.561

Review 10.  Tumor-Derived Exosomes in Immunosuppression and Immunotherapy.

Authors:  Wioletta Olejarz; Agnieszka Dominiak; Aleksandra Żołnierzak; Grażyna Kubiak-Tomaszewska; Tomasz Lorenc
Journal:  J Immunol Res       Date:  2020-05-22       Impact factor: 4.818

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.